ArticleChinese medical journal2026
Incidence, DALYs, and death rates of chronic kidney disease in China, 1990-2023: Results from the Global Burden of Disease Study 2023.
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a global public health concern that causes a remarkable disease burden. Although the prevalence of CKD in China has been investigated by previous national surveys, the incidence, disability-adjusted life years (DALYs), and death of CKD and their temporal trends over the past decades have not been well studied.
methodsIncidence, DALYs, and death of CKD, as well as risk-attributable DALYs and death in China from 1990 to 2023, were checked from the Global Burden of Diseases, Injuries, and Risk Factors Study 2023. The temporal trend of each indicator was estimated by join point analysis.
resultsIn 2023, in China, there were 156.15 (95% uncertainty interval: 146.77-167.88) million patients with CKD. The incidence, DALYs, and death rates of CKD were 240.59 (222.83-266.12), 355.86 (303.29-407.63), and 10.73 (8.96-12.70) per 100,000 population, respectively. Females had a higher incidence but lower DALYs and death rates than males. The elderly population had a much higher disease burden than middle-aged and young people. Incidence rates markedly increased, DALY rates slightly decreased, while death rates mildly increased from 1990 to 2023 with the respective average annual percent change of 1.67%, -0.17%, and 0.40%. However, the metrics all tended to decline after age standardization. Metabolic risk factors accounted for higher risk-attributable DALYs and deaths than other risk factors. High fasting plasma glucose ranked first in 2023 for risk-attributable DALYs and death, while high body mass index was the only risk factor maintaining a nondeclining contribution when comparing 2010 to 2023.
conclusionsCKD bears high levels of incidence, DALYs, and death in China, with an increasing trend for incidence observed from 1990 to 2023. The aging of the population and metabolic diseases are the main drivers of the CKD burden. Priority should be given to curb the CKD epidemic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.